Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 2/2010

Open Access 01-04-2010 | Research article

Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers

Authors: Chang Hoon Song, So Yeon Park, Keun-Yong Eom, Jee Hyun Kim, Sung-Won Kim, Jae Sung Kim, In Ah Kim

Published in: Breast Cancer Research | Issue 2/2010

Login to get access

Abstract

Introduction

Evaluating the expression of signaling molecule proteins from the mitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3-kinase (PI3K) pathway in invasive breast cancers may identify prognostic marker(s) associated with early relapse.

Methods

Immunohistochemical analyses of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), PI3K-p110α, phospho-AKT, phospho-p70S6 kinase, phospho-S6 ribosomal protein, phospho-RAF, phospho-p44/42 MAPK, and heat-shock protein 90 (HSP90) were performed on tumor samples from 212 patients with invasive breast cancer. Statistically significant relations between protein expression, clinicopathologic factors, and relapse-free survival (RFS) were analyzed.

Results

Expression of HSP90 was associated with 5-year RFS, as well as T stage, N stage, histologic grade, estrogen receptor (ER) expression, human epidermal growth factor receptor 2 (HER2) expression, and the Ki-67 proliferation index. On multivariate analysis, coexpression of HSP90 and PI3K-p110α or expression of HSP90 along with PTEN loss demonstrated significantly worse RFS. In subgroup analyses, both exhibited strong prognostic significance in HER2-positive cases, but not in HER2-negative cases.

Conclusions

The coexpression of HSP90 with PI3K-p110α or expression of HSP90 along with PTEN loss has a potential as a molecular prognostic marker to predict early relapse in patients with invasive breast cancers.
Appendix
Available only for authorised users
Literature
1.
Henson DE, Ries L, Freedman LS, Carriaga M: Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer: the basis for a prognostic index. Cancer. 1991, 68: 2142-2149. 10.1002/1097-0142(19911115)68:10<2142::AID-CNCR2820681010>3.0.CO;2-D.CrossRefPubMed
2.
Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.CrossRefPubMed
3.
Clark GM, McGuire WL, Hubay CA, Pearson OH, Carter A: The importance of estrogen and progesterone receptor in primary breast cancer. Prog Clin Biol Res. 1983, 132E: 183-190.PubMed
4.
Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol. 1992, 10: 1284-1291.PubMed
5.
Grann VR, Troxel AB, Zojwalla NJ, Grann VR, Troxel AB, Zojwalla NJ: Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer. 2005, 103: 2241-2251. 10.1002/cncr.21030.CrossRefPubMed
6.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182. 10.1126/science.3798106.CrossRefPubMed
7.
Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990, 8: 103-112.PubMed
8.
Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, Coates AS, Collins J, Castiglione-Gertsch M, Gusterson BA, the International Breast Cancer Study Group: Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors: a surrogate marker?. Cancer. 2003, 97: 1321-1331. 10.1002/cncr.11188.CrossRefPubMed
9.
Schlessinger J: Common and distinct elements in cellular signaling via EGF and FGF receptors. Science. 2004, 306: 1506-1507. 10.1126/science.1105396.CrossRefPubMed
10.
Huang MC, Lau YK: Basic science of HER2/neu: a review. Semin Oncol. 1999, 26: 51-59.
11.
Yarden Y, Sliwkowski M: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.CrossRefPubMed
12.
Neckers L, Ivy SP: Heat shock protein 90. Curr Opin Oncol. 2003, 15: 419-424. 10.1097/00001622-200311000-00003.CrossRefPubMed
13.
Eralp Y, Derin D, Ozluk Y, Yavuz E, Guney N, Saip P, Muslumanoglu M, Igci A, Kücücük S, Dincer M, Aydiner A, Topuz E: MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol. 2008, 19: 669-674. 10.1093/annonc/mdm522.CrossRefPubMed
14.
Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY: PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol. 2008, 15: 1064-1069. 10.1245/s10434-007-9751-7.CrossRefPubMed
15.
Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, Koujak S, Ferrando AA, Malmström P, Memeo L, Isola J, Bendahl PO, Rosen N, Hibshoosh H, Ringnér M, Borg A, Parsons R: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA. 2007, 104: 7564-7569. 10.1073/pnas.0702507104.CrossRefPubMedPubMedCentral
16.
Schmitz KJ, Otterbach F, Callies R, Levkau B, Hölscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW, Baba HA: Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases. Mod Pathol. 2004, 17: 15-21. 10.1038/modpathol.3800002.CrossRefPubMed
17.
Perez-Tenorio G, Stal O: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer. 2002, 86: 540-545. 10.1038/sj.bjc.6600126.CrossRefPubMedPubMedCentral
18.
Hage van der JA, Broek van den LJ, Legrand C, Clahsen PC, Bosch CJ, Robanus-Maandag EC, Velde van de CJ, Vijver van de MJ: Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer. 2004, 90: 1543-1550. 10.1038/sj.bjc.6601741.CrossRefPubMedPubMedCentral
19.
Bose S, Chandran S, Mirocha JM, Bose N: The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 2006, 19: 238-245. 10.1038/modpathol.3800525.CrossRefPubMed
20.
Pick E, Kluger Y, Giltnane JM, Moeder C, Camp RL, Rimm DL, Kluger HM: High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007, 67: 2932-2937. 10.1158/0008-5472.CAN-06-4511.CrossRefPubMed
21.
Hyun CL, Lee HE, Kim KS, Kim SW, Kim JH, Choe G, Park SY: The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer. J Clin Pathol. 2008, 61: 317-321. 10.1136/jcp.2007.050336.CrossRefPubMed
22.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
23.
Hanahan D, Weinberg R: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.CrossRefPubMed
24.
Engelman JA, Luo J, Catley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006, 7: 606-619. 10.1038/nrg1879.CrossRefPubMed
25.
Lee JY, Engelman JA, Catley LC: PI3K charges ahead. Science. 2007, 317: 206-207. 10.1126/science.1146073.CrossRefPubMed
26.
Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J: Frequent mutation of PI3KA gene in ovarian an d breast cancers. Clin Can Res. 2005, 11: 2875-2878. 10.1158/1078-0432.CCR-04-2142.CrossRef
27.
Cully M, You H, Levine AJ, Mak TW, Cully M, You H, Levine AJ, Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006, 6: 184-192. 10.1038/nrc1819.CrossRefPubMed
28.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, Vijver van de MJ, Bernards R: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007, 12: 395-402. 10.1016/j.ccr.2007.08.030.CrossRefPubMed
29.
Kim IA, Bae SS, Fernandes AM, Wu JM, Muschel RJ, McKenna GW, Birnbaum MJ, Bernhard EJ: Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res. 2005, 65: 7902-7910.PubMed
30.
No M, Choi EJ, Kim IA: Targeting HER2 signaling pathway for radiosensitization: alternative strategy for therapeutic resistance. Cancer Biol Ther. 2009, 8: 2351-2361. 10.1158/1535-7163.MCT-08-0801.CrossRefPubMed
31.
Powers M, Workman P: Targeting multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006, 13: S125-S135. 10.1677/erc.1.01324.CrossRefPubMed
32.
Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ: A high-affinity conformation of HSP90 confers tumour selectivity on HSP90 inhibitors. Nature. 2003, 425: 407-410. 10.1038/nature01913.CrossRefPubMed
33.
Munster PN, Basso A, Solit D, Norton L, Rosen N: Modulation of HSP90 function by ansamycin sensitize breast cancer cells to chemotherapy-induced apoptosis in a RB- and schedule-dependent manner. Clin Cancer Res. 2001, 7: 2228-2236.PubMed
34.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM: Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006, 355: 560-569. 10.1056/NEJMoa052933.CrossRefPubMed
35.
Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10: R65-10.1186/bcr2124.CrossRefPubMedPubMedCentral
36.
Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T: Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 2008, 10: R101-10.1186/bcr2204.CrossRefPubMedPubMedCentral
Metadata
Title
Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers
Authors
Chang Hoon Song
So Yeon Park
Keun-Yong Eom
Jee Hyun Kim
Sung-Won Kim
Jae Sung Kim
In Ah Kim
Publication date
01-04-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2557

Other articles of this Issue 2/2010

Breast Cancer Research 2/2010 Go to the issue

Research article

Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins

Research article

Effects of childhood body size on breast cancer tumour characteristics

Viewpoint

On the theory of tumor self-seeding: implications for metastasis progression in humans

Research article

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial

Research article

Trichostatin A enhances acetylation as well as protein stability of ERα through induction of p300 protein

Review

Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits